関節炎市場：治療タイプ別、疾患タイプ別、投与経路別、流通チャネル別、地域別、機会、予測、2017年～2031年

世界の関節炎の市場規模は、予測期間の2024年～2031年に6.00%のCAGRで拡大し、2023年の600億3,000万米ドルから2031年には956億8,000万米ドルに成長すると予測されています。関節炎市場は、人口の高齢化と相まって関節炎の疾病負担が増大していること、およびこの分野における新薬の開発・承認活動により、今後の成長に大きな影響を受けています。

関節炎は、関節の炎症として認識することができます。様々なタイプの関節炎には、関節リウマチ、変形性関節症、乾癬性関節炎、痛風、ループス、および他のタイプの関節炎が含まれます。関節炎の治療選択肢は、患者の病因や重症度に応じて、鎮痛剤から手術まで多岐にわたります。関節炎の治療市場は、成人の座りがちなライフスタイルや運動不足の副作用と、早期診断の重視の強化により、顕著なペースで成長すると予想されています。ヘルスケア組織によって推進されたイニシアチブの影響として、関節炎に関する一般の人々の間で意識が高まっているため、治療費の急増があり、市場の成長をさらに促進しています。しかし、主な課題としては、関節炎に使用される鎮痛剤に伴う副作用や、治療期間の長期化が挙げられます。

さらに、自己免疫性関節炎や乾癬性関節炎を含む様々なタイプの関節炎に対応する生物学的製剤の進歩は、将来的に市場に革命を起こすと予想されています。例えば、2024年9月、UCB Biopharma SRLは、生物学的製剤BIMZELX（bimekizumab-bkzx）の米国食品医薬品局（FDA）承認取得を発表しました。BIMZELXは、活動性の乾癬性関節炎（PsA）、客観的な炎症徴候を伴う活動性の非放射線性腋窩脊椎関節炎（nr-axSpA）、活動性の強直性脊椎炎（AS）の3つのカテゴリーに分類される成人患者を対象としています。この3つの適応症で承認された初めての治療薬であり、炎症プロセスを促進する2つの重要なサイトカイン、インターロイキン17A（IL-17A）とインターロイキン17F（IL-17F）を選択的に阻害するように設計されています。

当レポートでは、世界の関節炎市場について調査し、市場の概要とともに、治療タイプ別、疾患タイプ別、投与経路別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の関節炎市場の見通し、2017年～2031年

• 市場規模の分析と予測
• 市場シェア分析と予測
• 市場マップ分析、2023年
  • 治療タイプ別
  • 疾患タイプ別
  • 投与経路別
  • 流通チャネル別
  • 地域別

第5章 北米の関節炎市場の見通し、2017年～2031年

第6章 欧州の関節炎市場の見通し、2017年～2031年

第7章 アジア太平洋の関節炎市場の見通し、2017年～2031年

第8章 南米の関節炎市場の見通し、2017年～2031年

第9章 中東・アフリカの関節炎市場の見通し、2017年～2031年

第10章 需要供給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

第16章 市場の動向と発展

第17章 規制枠組みとイノベーション

第18章 特許の情勢

第19章 ケーススタディ

第20章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要参入企業トップ10の情勢
  • Novartis AG
  • Eli Lilly and Company
  • Amgen, Inc.
  • Viatris Inc.
  • Bristol-Myers Squibb Company
  • Pfizer, Inc.
  • AbbVie, Inc.
  • Janssen Global Services, LLC
  • F. Hoffmann-La Roche Ltd
  • Sanofi S.A.

第21章 戦略的提言

第22章 お問い合わせと免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 3. Global Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 4. Global Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 5. Global Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 6. Global Arthritis Market Share (%), By Region, 2017-2031F
• Figure 7. North America Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 8. North America Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 9. North America Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 10. North America Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 11. North America Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 12. North America Arthritis Market Share (%), By Country, 2017-2031F
• Figure 13. United States Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 14. United States Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 15. United States Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 16. United States Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 17. United States Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 18. Canada Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 19. Canada Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 20. Canada Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 21. Canada Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 22. Canada Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 23. Mexico Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 24. Mexico Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 25. Mexico Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 26. Mexico Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 27. Mexico Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 28. Europe Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 29. Europe Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 30. Europe Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 31. Europe Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 32. Europe Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 33. Europe Arthritis Market Share (%), By Country, 2017-2031F
• Figure 34. Germany Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 35. Germany Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 36. Germany Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 37. Germany Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 38. Germany Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 39. France Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 40. France Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 41. France Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 42. France Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 43. France Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 44. Italy Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 45. Italy Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 46. Italy Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 47. Italy Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 48. Italy Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 49. United Kingdom Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 50. United Kingdom Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 51. United Kingdom Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 52. United Kingdom Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 53. United Kingdom Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 54. Russia Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 55. Russia Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 56. Russia Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 57. Russia Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 58. Russia Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 59. Netherlands Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 60. Netherlands Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 61. Netherlands Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 62. Netherlands Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 63. Netherlands Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 64. Spain Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 65. Spain Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 66. Spain Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 67. Spain Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 68. Spain Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 69. Turkey Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 70. Turkey Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 71. Turkey Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 72. Turkey Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 73. Turkey Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 74. Poland Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 75. Poland Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 76. Poland Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 77. Poland Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 78. Poland Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 79. South America Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 80. South America Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 81. South America Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 82. South America Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 83. South America Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 84. South America Arthritis Market Share (%), By Country, 2017-2031F
• Figure 85. Brazil Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 86. Brazil Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 87. Brazil Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 88. Brazil Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 89. Brazil Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 90. Argentina Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 91. Argentina Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 92. Argentina Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 93. Argentina Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 94. Argentina Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 95. Asia-Pacific Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 96. Asia-Pacific Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 97. Asia-Pacific Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 98. Asia-Pacific Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 99. Asia-Pacific Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 100. Asia-Pacific Arthritis Market Share (%), By Country, 2017-2031F
• Figure 101. India Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 102. India Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 103. India Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 104. India Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 105. India Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 106. China Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 107. China Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 108. China Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 109. China Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 110. China Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 111. Japan Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 112. Japan Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 113. Japan Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 114. Japan Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 115. Japan Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 116. Australia Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 117. Australia Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 118. Australia Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 119. Australia Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 120. Australia Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 121. Vietnam Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 122. Vietnam Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 123. Vietnam Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 124. Vietnam Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 125. Vietnam Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 126. South Korea Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 127. South Korea Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 128. South Korea Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 129. South Korea Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 130. South Korea Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 131. Indonesia Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 132. Indonesia Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 133. Indonesia Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 134. Indonesia Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 135. Indonesia Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 136. Philippines Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 137. Philippines Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 138. Philippines Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 139. Philippines Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 140. Philippines Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 141. Middle East & Africa Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 142. Middle East & Africa Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 143. Middle East & Africa Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 144. Middle East & Africa Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 145. Middle East & Africa Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 146. Middle East & Africa Arthritis Market Share (%), By Country, 2017-2031F
• Figure 147. Saudi Arabia Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 148. Saudi Arabia Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 149. Saudi Arabia Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 150. Saudi Arabia Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 151. Saudi Arabia Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 152. UAE Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 153. UAE Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 154. UAE Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 155. UAE Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 156. UAE Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 157. South Africa Arthritis Market, By Value, In USD Billion, 2017-2031F
• Figure 158. South Africa Arthritis Market Share (%), By Treatment Type, 2017-2031F
• Figure 159. South Africa Arthritis Market Share (%), By Disease Type, 2017-2031F
• Figure 160. South Africa Arthritis Market Share (%), By Route of Administration, 2017-2031F
• Figure 161. South Africa Arthritis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 162. By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 163. By Disease Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 164. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 165. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global arthritis market is projected to witness a CAGR of 6.00% during the forecast period 2024-2031, growing from USD 60.03 billion in 2023 to USD 95.68 billion in 2031. The arthritis market is greatly influenced by future growth due to the growing disease burden of arthritis coupled with the aging population and novel drug development and approval activities in the field.

Arthritis can be recognized as inflammation of joints. Various types of arthritis include rheumatoid arthritis, osteoarthritis, psoriatic arthritis, gout, lupus, and other types of arthritis. The treatment options for arthritis range from analgesics to surgery, depending on the etiology and severity of the patient's condition. The treatment market for arthritis is anticipated to grow at a notable pace owing to the side effects of a sedentary lifestyle and lack of exercise among adults coupled with enhanced emphasis on early diagnoses. As awareness is increasing among common people about arthritis as an impact of initiatives driven by healthcare organizations, there is a surge towards treatment expense, further driving the market growth. The market lies in a high growth quarter; however, the major challenges include side effects associated with analgesics used for arthritis and longer duration of treatment.

Additionally, advancements in biologics addressing the various types of arthritis, including autoimmune-caused arthritis and psoriatic arthritis, are anticipated to revolutionize the market in the future. For instance, in September 2024, UCB Biopharma SRL announced receipt of US Food and Drug Administration (FDA) approval for its biologic drug BIMZELX (bimekizumab-bkzx). BIMZELX is meant for three categories of patients: adults with active psoriatic arthritis (PsA), adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and adults with active ankylosing spondylitis (AS). It is the first approved treatment for these three indications, designed to selectively inhibit two key cytokines driving inflammatory processes, interleukin 17A (IL-17A) and interleukin 17F (IL-17F).

Rising Prevalence of Arthritis to Boost Market Demand

The global prevalence of arthritis is gradually increasing, thus enhancing the demand for arthritic treatments. With a significant increase in the global population, the incidence of arthritis, primarily osteoarthritis and rheumatoid arthritis, continues to rise, leading to a higher number of patients requiring effective therapies. This is compounded by lifestyle-related issues, such as obesity, which increases the risk of arthritis. Healthcare professionals focus more on advanced treatment methods, including biologics, disease-modifying antirheumatic drugs (DMARDs), and other advanced therapies like gene therapy and regenerative medicine. Investments and research funding have also picked up, with the number of treatments rising rapidly, which is a typical indicator of market growth in arthritis. There is also rising awareness about the disease and its consequences on quality of life, which leads to early diagnosis and proactive management, fueling market growth. For instance, according to the Australian Institute of Health and Welfare, around 3.7 million (15%) people in Australia are estimated to be living with arthritis. Similarly, according to the Centers for Disease Control and Prevention, 21.2% of adults (i.e., 53.2 million) in the United States suffer from arthritis.

Advancements in Research to Tackle Arthritis Drives the Market

Advances in research in dealing with arthritis drive the market as it facilitates the development of innovative therapies and treatment modalities. Advanced research is opening rather complex biological mechanisms that lie behind the pathogenesis of arthritis. As a result, new targets have emerged, and novel biologics and DMARDs have been developed through innovations for a better effectiveness profile with minimal adverse effects than traditional drugs. Further, the developments of regenerative medicine for the future with stem cell therapies and tissue engineering hold vast promise in terms of relief and even cures for severe conditions. Understanding genetics and personalized medicine ensures treatment is increasingly targeted to individual patient profiles, improving outcomes and adherence. When stakeholders invest heavily in research and development, the pipeline of innovative therapies for arthritis attracts market interest and enables growth in the market.

For instance, the Further Consolidated Appropriations Act of 2024 provides USD 10 million for a new peer-reviewed arthritis research program (ATRP) managed by the Congressionally Directed Medical Research Programs. The goal of the program is to reduce the detrimental impact of arthritis on people in the United States.

Osteoarthritis Segment to Dominate the Market

The Osteoarthritis segment is anticipated to dominate the arthritis market, owing to its overall high prevalence and high prevalence among the elderly. Among the most common types of arthritis, osteoarthritis strikes millions around the world, so healthcare providers and pharmaceutical companies focus primarily on this type. Lifestyle factors such as obesity have caused a sharp surge in cases of osteoarthritis, thereby forcing demand for effective treatment options. Furthermore, patients with osteoarthritis who are going through life-changing disabilities are the main driving force for the market. Initiatives from market players to address osteoarthritis are further boosting the market. In September 2024, Sun Pharmaceutical Industries Limited and Israel-based Moebius Medical Limited announced that the USFDA had granted Fast Track designation (FTD) to MM-II (Large Liposomes of DPPC and DMPC) for treating osteoarthritis knee pain. Plans for confirmatory Phase 3 clinical trials for MMII are currently in progress. The FDA's Fast Track program is designed to facilitate the development and expedite the review of therapies intended to treat serious conditions and address unmet medical needs, potentially bringing important new medicines to patients earlier. Companies whose investigational products are granted FTD are eligible for more frequent interactions with the FDA during clinical development and potentially accelerated approval and/or priority review, among other benefits.

North America Dominates the Arthritis Market

North America currently dominates the arthritis market, primarily due to its superior healthcare infrastructural standards, higher prevalence of arthritis, and significant healthcare expenses. It has a large geriatric population, which is highly prone to arthritis, especially osteoarthritis and rheumatoid arthritis. The increased incidence prompts requirements for better treatment options and management plans within this age segment. In addition, there are pharmaceutical majors and research institutes from the United States that are innovating in arthritis therapies, such as biologics and personalized medicine. The regulatory structure also supports ease in drug approval, and reimbursement mechanisms already exist. In addition, increased awareness of the disease coupled with decreased quality of life due to arthritis triggers positive and proactive healthcare measures, along with earlier diagnosis and consequently increased treatment. For instance, according to the Osteoarthritis Action Alliance, 1 in 5 adults in the United States have some form of arthritis. While there are estimated to be more than 100 types of arthritis, osteoarthritis is the most common form, affecting 32.5 million adults in the United States. The projected number of arthritis patients in the United States is 78 million by 2040.

Future Market Scenario (2024-2031F)

Advances in biologics are key drivers in the arthritic market since the market players are focused on developing therapies that target specific mechanisms of disease. Advanced therapies, like monoclonal antibodies and fusion proteins, better manage diseases such as rheumatoid arthritis and psoriatic arthritis, thus improving the outcomes of patients and their quality of life. As the number of new biologic agents continues to become well-indexed in ongoing research, healthcare providers will adopt these therapies even more aggressively. For instance, in October 2023, Novartis AG received approval from the US Food and Drug Administration (FDA) for its drug Cosentyx (secukinumab), which is intended to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the first fully human biologic that specifically targets and blocks interleukin-17A (IL-17A), an important cytokine involved in the inflammation of psoriatic arthritis (PsA), moderate to severe plaque psoriasis, ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA).

Key Players Landscape and Outlook

The market for arthritis treatments is being dominated by global players like Eli Lilly and Company, Viatris Inc., and others. The market is quite vast with various generic and branded drugs, which makes the market distributed among a large number of small players and a bunch of global players. Notable activities in the market include mutual business agreements, and divestment to grow alternate business units.

In September 2024, Eli Lilly and Company and EVA Pharma agreed to expand access to baricitinib for an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. Baricitinib is used to treat rheumatoid arthritis, alopecia areata, atopic dermatitis, and COVID-19. EVA Pharma's high-containment facility will start selling locally manufactured baricitinib to various African countries by 2026. This collaboration leverages EVA's pan-African reach and strong local manufacturing capabilities that meet global standards, allowing Lilly to reach more people in low- to middle-income countries.

In April 2024, Crescent Innovations, Inc. announced the sale of its Poly-gamma-glutamic Acid (PgGA) technology, which is related to osteoarthritis (OA), along with various intellectual property and know-how assets. PgGA was developed as the next generation of viscosupplements for treating degenerative joint disease. Unlike the current state-of-the-art OA treatment, hyaluronic acid (HA), PgGA has triple the charge density of HA, making it unique in its charge density.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Arthritis Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Treatment Type
    • 4.2.1.1. Drugs
      • 4.2.1.1.1. Biologics
      • 4.2.1.1.2. Non-Biologics
        • 4.2.1.1.2.1. Disease-modifying Antirheumatic Drugs (DMARDs)
        • 4.2.1.1.2.2. Tumor Necrosis Factor (TNF) Inhibitors
        • 4.2.1.1.2.3. Interleukin Inhibitors
        • 4.2.1.1.2.4. Non-steroidal anti-inflammatory drugs (NSAIDs)
        • 4.2.1.1.2.5. Corticosteroids
        • 4.2.1.1.2.6. Xanthine Oxidase Inhibitors
        • 4.2.1.1.2.7. Others
    • 4.2.1.2. Assistive Devices
    • 4.2.1.3. Therapy
    • 4.2.1.4. Surgery
  • 4.2.2. By Disease Type
    • 4.2.2.1. Rheumatoid Arthritis
    • 4.2.2.2. Osteoarthritis
    • 4.2.2.3. Psoriatic Arthritis
    • 4.2.2.4. Gout
    • 4.2.2.5. Lupus
    • 4.2.2.6. Others
  • 4.2.3. By Route of Administration
    • 4.2.3.1. Oral
    • 4.2.3.2. Parenteral
    • 4.2.3.3. Topical
  • 4.2.4. By Distribution Channel
    • 4.2.4.1. Hospital and Clinics
    • 4.2.4.2. Retail Pharmacies
    • 4.2.4.3. Online Pharmacies
  • 4.2.5. By Region
    • 4.2.5.1. North America
    • 4.2.5.2. Europe
    • 4.2.5.3. Asia-Pacific
    • 4.2.5.4. South America
    • 4.2.5.5. Middle East and Africa
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Treatment Type
  • 4.3.2. By Disease Type
  • 4.3.3. By Route of Administration
  • 4.3.4. By Distribution Channel
  • 4.3.5. By Region

5. North America Arthritis Market Outlook, 2017-2031F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Treatment Type
    • 5.2.1.1. Drugs
      • 5.2.1.1.1. Biologics
      • 5.2.1.1.2. Non-Biologics
        • 5.2.1.1.2.1. Disease-modifying Antirheumatic Drugs (DMARDs)
        • 5.2.1.1.2.2. Tumor Necrosis Factor (TNF) Inhibitors
        • 5.2.1.1.2.3. Interleukin Inhibitors
        • 5.2.1.1.2.4. Non-steroidal anti-inflammatory drugs (NSAIDs)
        • 5.2.1.1.2.5. Corticosteroids
        • 5.2.1.1.2.6. Xanthine Oxidase Inhibitors
        • 5.2.1.1.2.7. Others
    • 5.2.1.2. Assistive Devices
    • 5.2.1.3. Therapy
    • 5.2.1.4. Surgery
  • 5.2.2. By Disease Type
    • 5.2.2.1. Rheumatoid Arthritis
    • 5.2.2.2. Osteoarthritis
    • 5.2.2.3. Psoriatic Arthritis
    • 5.2.2.4. Gout
    • 5.2.2.5. Lupus
    • 5.2.2.6. Others
  • 5.2.3. By Route of Administration
    • 5.2.3.1. Oral
    • 5.2.3.2. Parenteral
    • 5.2.3.3. Topical
  • 5.2.4. By Distribution Channel
    • 5.2.4.1. Hospital and Clinics
    • 5.2.4.2. Retail Pharmacies
    • 5.2.4.3. Online Pharmacies
  • 5.2.5. By Country Share
    • 5.2.5.1. United States
    • 5.2.5.2. Canada
    • 5.2.5.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Arthritis Market Outlook, 2017-2031F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Treatment Type
        • 5.3.1.2.1.1. Drugs
        • 5.3.1.2.1.1.1. Biologics
        • 5.3.1.2.1.1.2. Non-Biologics
        • 5.3.1.2.1.1.2.1. Disease-modifying Antirheumatic Drugs (DMARDs)
        • 5.3.1.2.1.1.2.2. Tumor Necrosis Factor (TNF) Inhibitors
        • 5.3.1.2.1.1.2.3. Interleukin Inhibitors
        • 5.3.1.2.1.1.2.4. Non-steroidal anti-inflammatory drugs (NSAIDs)
        • 5.3.1.2.1.1.2.5. Corticosteroids
        • 5.3.1.2.1.1.2.6. Xanthine Oxidase Inhibitors
        • 5.3.1.2.1.1.2.7. Others
        • 5.3.1.2.1.2. Assistive Devices
        • 5.3.1.2.1.3. Therapy
        • 5.3.1.2.1.4. Surgery
      • 5.3.1.2.2. By Disease Type
        • 5.3.1.2.2.1. Rheumatoid Arthritis
        • 5.3.1.2.2.2. Osteoarthritis
        • 5.3.1.2.2.3. Psoriatic Arthritis
        • 5.3.1.2.2.4. Gout
        • 5.3.1.2.2.5. Lupus
        • 5.3.1.2.2.6. Others
      • 5.3.1.2.3. By Route of Administration
        • 5.3.1.2.3.1. Oral
        • 5.3.1.2.3.2. Parenteral
        • 5.3.1.2.3.3. Topical
      • 5.3.1.2.4. By Distribution Channel
        • 5.3.1.2.4.1. Hospital and Clinics
        • 5.3.1.2.4.2. Retail Pharmacies
        • 5.3.1.2.4.3. Online Pharmacies
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Arthritis Market Outlook, 2017-2031F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Arthritis Market Outlook, 2017-2031F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Arthritis Market Outlook, 2017-2031F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Arthritis Market Outlook, 2017-2031F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

• 17.1. Clinical Trials
• 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Novartis AG
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 20.3.2. Eli Lilly and Company
  • 20.3.3. Amgen, Inc.
  • 20.3.4. Viatris Inc.
  • 20.3.5. Bristol-Myers Squibb Company
  • 20.3.6. Pfizer, Inc.
  • 20.3.7. AbbVie, Inc.
  • 20.3.8. Janssen Global Services, LLC
  • 20.3.9. F. Hoffmann-La Roche Ltd
  • 20.3.10. Sanofi S.A.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer